|
Market Closed -
Nasdaq
01:30:00 02/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 75.46 USD | -4.01% |
|
-0.66% | -7.84% |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 3,311 | - | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | -4.73% | - | - |
| Enterprise Value (EV) 1 | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 2,975 | 2,836 | 2,618 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | -14.4% | -4.68% | -7.68% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -15.5x | 984x | 21x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -0x | -10x | 0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 4.59x | 3.57x | 2.85x |
| EV / Revenue | 8.16x | 15.1x | 27.1x | 10.4x | 7.7x | 4.13x | 3.06x | 2.25x |
| EV / EBITDA | -39.3x | -6.27x | -3.32x | -15.8x | -50.3x | -31.5x | 62.5x | 21.2x |
| EV / EBIT | -38.3x | -6.24x | -3.3x | -15.7x | -49x | -13.3x | 511x | 13.9x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -4.862 | 0.0767 | 3.6 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 721.1 | 927.2 | 1,162 |
| EBITDA 1 | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | -94.3 | 45.39 | 123.6 |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -224.2 | 5.547 | 187.7 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -218.5 | 6.898 | 203 |
| Net Debt 1 | - | - | -198.3 | -222.5 | - | -336.3 | -475.6 | -693.3 |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 75.46 | 75.46 | 75.46 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,883 | - | - |
| Announcement Date | 14/03/22 | 13/03/23 | 27/02/24 | 25/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -16.17x | 4.32x | -33.01x | -.--% | 331.14Cr | |
| 32.9x | 11.93x | 24.23x | 0.6% | 1,02500Cr | |
| 29.45x | 6.54x | 18.31x | 2.02% | 62TCr | |
| 33.1x | 7.75x | 16.02x | 2.65% | 46TCr | |
| 105.72x | 5.91x | 25.05x | 2.35% | 35TCr | |
| 19x | 4.63x | 11.48x | 2.87% | 34TCr | |
| 20.37x | 5.28x | 13.08x | 3.03% | 27TCr | |
| 20.79x | 4.31x | 12.28x | 2.05% | 25TCr | |
| 26.62x | 6.92x | 12.32x | 2.39% | 22TCr | |
| -45.08x | 6.57x | 25.65x | 2.21% | 18TCr | |
| Average | 22.67x | 6.42x | 12.54x | 2.02% | 37.22TCr | |
| Weighted average by Cap. | 32.07x | 7.72x | 18.86x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
